TriMas Corp

TriMas Corp (TRS) Stock Analysis

$38.750

-0.198 (-0.51%)At close

Loading chart…
High
39.485
Open
39.060
VWAP
38.93
Volume
345.70K
Mkt Cap
1.03B
Low
38.545
Amount
13.46M
EV/EBITDA, TTM
5.66

TriMas Corporation designs, manufactures and supplies a range of products for the consumer packaging and industrial markets through its TriMas Packaging and Specialty Products groups. The Company's segments include Packaging and Specialty Products. Its Packaging segment offers dispensing, closure and flexible packaging solutions, including Rieke, Affaba & Ferrari, Taplast, Rapak and Aarts Packaging, along with Intertech and Omega Plastics, which provide life sciences–focused products. Its Packaging business develops and manufactures an array of dispensing products, polymeric and steel caps and closures, polymeric jar products, fully integrated dispensers for fill-ready bag-in-box applications, and consumable vascular delivery and diagnostic test components, all for a variety of consumer products submarkets. Its Specialty Products segment, which includes the Norris Cylinder business, designs, manufactures and distributes highly engineered steel cylinders.

trimas.com

AI analysis of TriMas Corp (TRS)

Hold

TriMas Corp (TRS) is currently priced at $38.75, with a forward P/E ratio of 19.34, indicating potential for growth but also suggesting it may not be undervalued at this time. The RSI is at 54.92, showing the stock is neither overbought nor oversold, which suggests a neutral stance. While the company has shown a year-to-date price increase of 6.78% and a positive earnings surprise of 6.12% in its last report, the significant hedge fund selling of 909.26% raises concerns about future price stability. Therefore, it may be prudent to hold rather than buy at this moment, as the risks from insider selling and market volatility could outweigh potential gains.

Analyst Ratings (6)

+7.10% upside
Hold
1 Buy
5 Hold
0 Sell
Current: 38.75
Low
38.00
Average
41.50
High
45.00

KeyBanc

2025-11-13

Price Target

$38

Overweight

KeyBanc

2025-08-13

Price Target

$45

Overweight

KeyBanc

2025-08-12

Price Target

$45

Overweight

BWS Financial

2025-07-30

Price Target

$45

Buy

BWS Financial

2025-02-28

Price Target

$40

Strong Buy

Valuation Metrics

The current forward P/E ratio for TriMas Corp (TRS) is 19.34, compared to its 5-year average forward P/E of 15.03.

Forward P/E

Fair
5Y Average P/E
15.03
Current P/E
19.34
Overvalued
19.42
Undervalued
10.64

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
8.49
Current EV/EBITDA
5.66
Overvalued
11.44
Undervalued
5.53

Forward P/S

Overvalued
5Y Average P/S
1.36
Current P/S
2.01
Overvalued
1.73
Undervalued
0.99

Alphio AI Price Scenarios for TRS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TRS

$24.42

Scenario price

B

Base

Base · 50%TRS

$23.53

Scenario price

B

Bear

Bear · 25%TRS

$21.04

Scenario price

Whales holding TRS

J

Jefferies Financial Group Inc.

+ HoldingTRS

+0.57%

3M Return

P

Punch & Associates Investment Management, Inc.

+ HoldingTRS

-5.54%

3M Return

Events Timeline

2026-07-30 (ET)

08:30:00

Sees FY26 Sales Growth of 3%-6%

2026-04-30 (ET)

08:10:00

Company Reaffirms 2026 Sales Growth of 3%-6%

08:10:00

TriMas Reports Q1 Revenue of $168.28M

2026-03-16 (ET)

11:40:00

TriMas Completes Aerospace Divestiture for Approximately $1.45B

2026-02-26 (ET)

08:40:00

TriMas Q4 Revenue $155.49M, Below Consensus

News

TRS FAQ — answered by Alphio AI

TriMas Corporation designs, manufactures and supplies a range of products for the consumer packaging and industrial markets through its TriMas Packaging and Specialty Products groups. The Company's segments include Packaging and Specialty Products. Its Packaging segment offers dispensing, closure and flexible packaging solutions, including Rieke, Affaba & Ferrari, Taplast, Rapak and Aarts Packaging, along with Intertech and Omega Plastics, which provide life sciences–focused products. Its Packaging business develops and manufactures an array of dispensing products, polymeric and steel caps and closures, polymeric jar products, fully integrated dispensers for fill-ready bag-in-box applications, and consumable vascular delivery and diagnostic test components, all for a variety of consumer products submarkets. Its Specialty Products segment, which includes the Norris Cylinder business, designs, manufactures and distributes highly engineered steel cylinders. It operates in the Basic Materials sector (METAL FORGINGS & STAMPINGS industry).

TriMas Corp (TRS) is currently priced at $38.75, with a forward P/E ratio of 19.34, indicating potential for growth but also suggesting it may not be undervalued at this time. The RSI is at 54.92, showing the stock is neither overbought nor oversold, which suggests a neutral stance. While the company has shown a year-to-date price increase of 6.78% and a positive earnings surprise of 6.12% in its last report, the significant hedge fund selling of 909.26% raises concerns about future price stability. Therefore, it may be prudent to hold rather than buy at this moment, as the risks from insider selling and market volatility could outweigh potential gains.

6 analysts cover TRS: 1 rate it Buy, 5 Hold and 0 Sell. The average price target is 41.50.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading